Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Zepbound sales totaled $4.9 billion worldwide last year, while Wegovy earned nearly $8.8 billion. Both drugs were recently removed from the U.S. Food and Drug Administration's shortage list.

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

There has been positive clinical trial news recently from Tirzepatide -- the active ingredient in both Mounjaro and Zepbound -- as well as insulin efsitora alfa, Eli Lilly's investigational once ...

Zepbound revenue soared from $175.8 million to $1.9 billion, while Mounjaro sales jumped 60% to $3.5 billion.

Quarterly sales for blockbuster diabetes drug Mounjaro totaled more than $3 billion. (George Frey/Reuters) Eli Lilly shares jumped after the drugmaker reported earnings that trumped analyst ...